Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: Tofacitinib

Tofacitinib Not Tied to More Malignancies in RA Patients

David Douglas  |  

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

Reuters Staff  |  

NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…

RA Research Presented at ACR Convergence 2025 in Focus

Jeffrey Curtis, MD, MS, MPH  |  

This synopsis of research into rheumatoid arthritis highlights key areas presented at ACR Convergence 2025, including strategies to delay or prevent RA, emerging mechanisms of action in RA treatment, and the growing role of AI in advancing RA research and clinical care.

ACR Releases New Guideline for Management of SLE at ACR 2025

Mithu Maheswaranathan, MD  |  

Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.

Management of Challenging Cases in Myositis

Michael Cammarata, MD  |  

Immune mediated inflammatory myopathies represent a heterogenous group of diseases with variable degrees of multisystem involvement, including the skin, joints, lungs, and muscles. The ACR Convergence 2025 session, Management of Challenging Cases in Myositis, featured a case-based approach to highlight this complexity, guiding attendees through the nuances of diagnosis and management of antisynthetase syndrome, immune mediated necrotizing myopathy, and dermatomyositis.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.